• IN4 POPULATION-BASED EVALUATION OF FUTURE BURDEN OF DISEASE AND COSTS RELATED TO CHRONIC HEPATITIS C AND ANTIVIRAL TREATMENT STRATEGIES

    Nov 1, 2004, 00:00

  • PCV23 ACUTE COSTS OF STROKE IN THE UK NATIONAL HEALTH SERVICE IN 2002-2004

    Nov 1, 2004, 00:00

  • PNL11 EFFECT OF COMORBIDITIES ON MEDICAL CARE USE AND COST AMONG PATIENTS WITH PARTIAL SEIZURE DISORDER

    Nov 1, 2004, 00:00

  • PIN7 COST MINIMIZATION ANALYSIS OF ORAL VALGANCICLOVIR VS. INTRAVENOUS AND ORAL GANCICLOVIR IN THE PREVENTION OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN SOLID ORGAN TRANSPLANT RECIPIENTS

    Nov 1, 2004, 00:00

  • PIN30 FREQUENCY OF POTENTIAL DRUG-DRUG INTERACTIONS WITH TRIAZOLE ANTIFUNGAL USE IN DUTCH HOSPITAL SETTINGS

    Nov 1, 2004, 00:00

  • PHP35 RESOURCE USE AND COSTS OF PATIENTS RECEIVING ENTERAL NUTRITION IN PRIMARY AND SECONDARY CARE IN THE UK

    Nov 1, 2004, 00:00

  • PCV56 PREVALENCE, AWARENESS, TREATMENT, AND CONTROL OF HYPERCHOLESTEROLEMIA AMONG CHINESE AMERICANS

    Nov 1, 2004, 00:00

  • PCVII COST EFFECTIVENESS OF ADDING NIASPANTO ATORVASTATIN TREATMENT IN THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN PATIENTS WITH DYSLIPIDEMIA IN THE UK

    Nov 1, 2004, 00:00

  • MH2 MODELING ANTIPSYCHOTICS MARKET SHARE EVOLUTION TREATMENT

    Nov 1, 2004, 00:00

  • UC2 PATIENTS PREFERENCES FOR INGUINAL HERNIA REPAIR

    Nov 1, 2004, 00:00

  • PGI1 ECONOMIC EVALUATION OF ON-DEMAND MAINTENANCE THERAPY WITH PROTON PUMP INHIBITORS IN PATIENTS WITH SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE-A MONTE-CARLO ANALYSIS FOR ITALY

    Nov 1, 2004, 00:00

  • PCV8 THE ECONOMIC IMPACT OF CLOPIDOGREL IN PATIENTS WITH UNSTABLE CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)- POLISH PERSPECTIVE

    Nov 1, 2004, 00:00

  • PMC10 ASP PLUS SIX PERCENT IN 2005-A CONCEPTUAL VIEW OF FUTURE PHYSICIAN PAYMENTS FOR DRUGS AND THEIR ADMINISTRATION IN THE OFFICE SETTING

    Nov 1, 2004, 00:00

  • PDB4 THE DIABETES TYPE-2 COST PREDICTORS

    Nov 1, 2004, 00:00

  • PIN4 COST-EFFECTIVENESS ANALYSIS OF LINEZOLID VERSUS VANCOMYCIN IN THE TREATMENT OF VENTILATORASSOCIATED PNEUMONIA IN SPAIN

    Nov 1, 2004, 00:00

  • PUK23 LANTHANUM CARBONATE FOR THE TREATMENT OF HYPERPHOSPHATAEMIA- DEVELOPMENT OF A COSTEFFECTIVENESS MODEL

    Nov 1, 2004, 00:00

  • PDB1 ASSOCIATION OF PATIENTS KNOWLEDGE AND ADHERENCE TO MEDICAL ADVICE TO GLYCAEMIC CONTROL IN THE MANAGEMENT OF DIABETES MELLITUS

    Nov 1, 2004, 00:00

  • CV6 WHAT IS THE ADDED VALUE OF HEALTH RELATED QUALITY OF LIFE (HRQL) DATA? AN EXAMPLE FROM THE INTERNATIONAL SUBARACHNOID ANEURYSM TRIAL (ISAT)

    Nov 1, 2004, 00:00

  • PIN11 PHARMACOECONOMIC EVALUATION OF HERD PROTECTION FOR THE SEVEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN SWITZERLAND

    Nov 1, 2004, 00:00

  • PES21 HAIR LOSS, QUALITY OF LIFE IMPACT

    Nov 1, 2004, 00:00

  • PGI11 PSYCHOMETRIC VALIDATION OF TWO GASTROINTESTINAL (GI)-SPECIFIC PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS IN RENAL TRANSPLANT PATIENTS WITH AND WITHOUT GI COMPLICATIONS

    Nov 1, 2004, 00:00

  • PRS2 COST OF CHRONIC BRONCHITIS (CB) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN FRANCE- THE BRONCHECO STUDY

    Nov 1, 2004, 00:00

  • PUK24 PREVALENCE AND QUALITY OF LIFE IN FRENCH WOMEN WITH STRESS URINARY INCONTINENCE

    Nov 1, 2004, 00:00

  • PUK10 A HEALTH ECONOMIC EVALUATION OF 6 MONTHS ALFUZOSIN TREATMENT IN THE MANAGEMENT OF ACUTE URINARY RETENTION

    Nov 1, 2004, 00:00

  • CV7 MODELLING SURVIVAL AND COSTS IN SWITZERLAND OF NESIRITIDE VERSUS INOTROPIC THERAPY FOR ACUTE DECOMPENSATED HEART FAILURE

    Nov 1, 2004, 00:00

  • PMH23 ADHD TREATMENT AND CO-MORBIDITIES- BASELINE RESULTS FROM THE OBSERVATIONAL STUDY ADORE IN GERMANY

    Nov 1, 2004, 00:00

  • PIN16 ECONOMIC BURDEN AND FACTORS INFLUENCING COSTS IN GERMAN PATIENTS HOSPITALISED FOR COMMUNITYACQUIRED PNEUMONIA (CAP)

    Nov 1, 2004, 00:00

  • PHP10 EMERGENCY DEPARTMENT VISITS FOR INJURIES RESULTING FROM BICYCLE ACCIDENTS- TIME, TYPE AND COST OF INJURY

    Nov 1, 2004, 00:00

  • PMC12 EVALUATING DRUG SAFETY USING STOCHASTIC SIMULATION MODELS

    Nov 1, 2004, 00:00

  • PHP5 DECISION MAKING IN ITALIAN HEALTH CARE- ARE ECONOMIC STUDIES USED BY DECISION MAKERS?

    Nov 1, 2004, 00:00

  • PIN25 ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE MEASURES IN HIV AND AIDS

    Nov 1, 2004, 00:00

  • PCNI2 COST EFFECTIVENESS OF AN ASPIRIN CHEMOPREVENTION AND/OR COLONOSCOPIC SURVEILLANCE IN THE COLORECTAL CANCER

    Nov 1, 2004, 00:00

  • PHP12 COST VARIANCES IN G-DRG GROUPS. THE EXAMPLE OF RHBMP-2 IN SPINE FUSION SURGERY

    Nov 1, 2004, 00:00

  • PIN21 COST-BENEFIT ANALYSIS OF ANTI-INFLUENZA VACCINATION IN A PUBLIC HEALTH CARE UNIT

    Nov 1, 2004, 00:00

  • PHP19 EFFECTS OF DEVOLUTION OF SUBSIDIES FOR PHARMACEUTICALS IN SWEDEN

    Nov 1, 2004, 00:00

  • PCVI8 COSTS OF HYPERTENSION IN THE ELDERLY IN COMPARISON WITH PATIENTS UNDER 65 IN POLAND

    Nov 1, 2004, 00:00

  • PMH28 METABOLIC OUTCOMES OF ANTIPSYCHOTICS IN SCHIZOPHRENIA- A MARKOV MODEL

    Nov 1, 2004, 00:00

  • PCV6 AN ECONOMIC EVALUATION OF CLOPIDOGREL VS. ASPIRIN IN SECONDARY PREVENTION OF ISCHEMIC EVENTS IN HIGH RISKATHEROTHROMBOTIC PATIENTS IN ITALY

    Nov 1, 2004, 00:00

  • PAR4 THE COART STUDY- THE COST OF OSTEOARTHRITIS IN FRANCE BETWEEN 1991 AND 2002

    Nov 1, 2004, 00:00

  • PHP22 MEDICATION AND SOCIO-ECONOMIC STATUS IN A POPULATION-BASED COHORT STUDY

    Nov 1, 2004, 00:00

  • UC4 VARIATION IN ADL FUNCTIONING WITHIN BARTHEL INDEX SCORES-IMPLICATIONS FOR STROKE CLINICAL TRIALS AND PRACTICE

    Nov 1, 2004, 00:00

  • PCN28 QUALITY OF LIFE AND SEXUALITY IN PATIENTS WITH RECTAL CANCER

    Nov 1, 2004, 00:00

  • PIN20 COST-MINIMIZATION ANALYSIS OF VORICONAZOLE AND CASPOFUNGIN FOR THE TREATMENT OF INVASIVE CANDIDA AND ASPERGILLOSIS INFECTIONS IN SPAIN

    Nov 1, 2004, 00:00

  • CN1 TRENDS IN OUTCOMES AND COSTS FOR U.S. PATIENTS WITH ADVANCED NON-SMALL LUNG CANCER 1994-2001

    Nov 1, 2004, 00:00

  • PHP4 PERSPECTIVE OF THE GENERIC MARKET IN FRANCE- 2004-2008

    Nov 1, 2004, 00:00

  • PES6 COST EFFECTIVENESS OF LATANOPROST IN FIRST LINE TREATMENT OF PRIMARY OPEN ANGLE GLAUCOMA IN THE UK

    Nov 1, 2004, 00:00

  • PAR22 FIBROMYALGIA SYNDROM- A FRENCH EPIDEMIOLOGICAL SURVEY

    Nov 1, 2004, 00:00

  • PARI HE BURDEN OFANKYLOSING SPONDYLITIS IN AUSTRALIA AN EPIDEMIOLOGICALAND COST OF ILLNESS MODEL

    Nov 1, 2004, 00:00

  • PCN5 COST-UTILITY ANALYSIS OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (EBC)- A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE

    Nov 1, 2004, 00:00

  • PMH30 COST-EFFECTIVENESS ANALYSIS IN THE AUSTRALIAN SETTING OF RISPERIDONE LONG-ACTING INJECTION FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA WHO ARE PARTIALLY ADHERENT TO THEIR MEDICATION

    Nov 1, 2004, 00:00

  • CV2 CHOLESTEROL ATTAINMENT IN DYSLIPIDAEMIC TREATED PATIENTS AND INCIDENCE OF CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE

    Nov 1, 2004, 00:00

  • PUK14 ELDERLY PATIENTS STARTING RENAL REPLACEMENT THERAPY (RRT) HAVE LOWER LOSS OF HEALTH RELATED QUALITY OF LIFE (HRQL) THAN YOUNGER ONES DURING THE FIRST TWO YEARS

    Nov 1, 2004, 00:00

  • PCV55 DISEASE SPECIFIC VERSUS GENERIC OUTCOME ASSESSMENT IN PULMONARY HYPERTENSION

    Nov 1, 2004, 00:00

  • POS9 EPIDEMIOLOGY OF OSTEOPOROSIS IN THE NETHERLANDS (1993-2002)

    Nov 1, 2004, 00:00

  • PDB7 LONG TERM COST EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30/70 VERSUS INSULIN GLARGINE IN INSULIN NAVE PATIENTS WITH TYPE-2 DIABETES POORLY CONTROLLED ON ORAL HYPOGLYCEMIC AGENTS IN DANISH, DUTCH, FINNISH, FRENCH, GERMAN, NORWEGIAN, SPA ...

    Nov 1, 2004, 00:00

  • PBR6 ISAM- INTERNATIONAL STUDY OF ANTICOAGULATION MANAGEMENT.THE ITALIAN EXPERIENCE

    Nov 1, 2004, 00:00

  • PMH11 PROBABILISTIC COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM VERSUS CITALOPRAM IN THE TREATMENT OF SEVERE DEPRESSION IN THE UNITED KINGDOM

    Nov 1, 2004, 00:00

  • PMH24 EFFECT OF ZIPRASIDONE INITIAL DOSING ON DISCONTINUATION IN SCHIZOPHRENIA

    Nov 1, 2004, 00:00

  • PCV42 PUBLIC HEALTH AND ECONOMIC IMPACTS OF RAISING THE LEGAL SMOKING AGE IN CALIFORNIA

    Nov 1, 2004, 00:00

  • PCNI9 NEW TARGETED THERAPY FOR PATIENTS WITH PREVIOUSLY-TREATED ADVANCED NON-SMALL CELL LUNG CANCER-GEFITINIB ('IRESSA')

    Nov 1, 2004, 00:00

  • POS4 COST-EFFECTIVENESS OF BONE STIMULATORS IN THE CONSERVATIVE TREATMENT OF STABLE NONUNION FRACTURES

    Nov 1, 2004, 00:00

  • PDB31 COMPARISON OF BLOOD PRESSURE AND ATTRIBUTABLE HEALTHCARE COSTS BY DIHYDROPYRIDINE VS NONDIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INITIATED FOR HYPERTENSION IN DIABETES MELLITUS PATIENTS, AND MONITORING OF RENAL PARAMETERS

    Nov 1, 2004, 00:00

  • PHP11 PRESCRIBING PATTERNS OF CIPROFLOXACIN AND LEVOFLOXACIN IN AN ITALIAN GERIATRIC HOSPITAL

    Nov 1, 2004, 00:00

  • PDB19 COST OF HOSPITAL ADMISSIONS FOR CARDIOVASCULAR DISEASE OVER FIVE YEARS IN PATIENTS WITH DIABETES MELLITUS

    Nov 1, 2004, 00:00

  • PES4 EFFECT OF CIRCADIAN INTRA-OCULAR PRESSURE VARIATIONS ON THERAPEUTIC DECISION MAKING- A MODELING APPROACH BASED ON A RANDOMIZED CLINICAL TRIAL

    Nov 1, 2004, 00:00

  • PIN31 COSTS AND EFFECTS OF CHLAMYDIAL SCREENING PROGRAMS- DYNAMIC VERSUS STATIC MODELING

    Nov 1, 2004, 00:00

  • PCV22 THE COST EFFECTIVENESS OF HORMONE REPLACEMENT THERAPY (HRT) FOR WOMEN WITH MENOPASUAL SYMPTOMS IN SWEDEN

    Nov 1, 2004, 00:00

  • PCV57 CHRONIC VENOUS DISEASE- COMPLIANCE WITH TREATMENT

    Nov 1, 2004, 00:00

  • PIN27 WILLINGNESS TO PAY FOR PREVENTION AND TREATMENT OF TUBERCULOSIS (TB) IN RURAL NEPAL- A CONTINGENT VALUATION STUDY

    Nov 1, 2004, 00:00

  • PIN15 ACUTE ROTAVIRUS GASTROENTERITIS- BURDEN OF DISEASE AND COST OF ILLNESS AMONG YOUNG CHILDREN IN GERMANY

    Nov 1, 2004, 00:00

  • PCV59 CHRONIC VENOUS DISEASE-THROUGH BODY MASS INDEX

    Nov 1, 2004, 00:00

  • PNL31 NEUROPATHIC PAIN (NEP) IMPACT ON PATIENT MENTAL FUNCTIONING, SYMPTOM LEVELS OF ANXIETY AND DEPRESSION, AND SLEEP DISTURBANCE- RESULTS FROM THE DONEGA STUDY

    Nov 1, 2004, 00:00

  • PCN2 COST-EFFECTIVENESS OF IMATINIB (GLEEVEC)AS FIRST-LINE TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)

    Nov 1, 2004, 00:00

  • PPN13 THE UNDER TREATMENT OF DEPRESSION IN CHRONIC PAIN

    Nov 1, 2004, 00:00

  • PCN4I ASSESSMENT OF DIFFERENT STRATEGIES FOR DETERMINING DIAGNOSIS AND RESECTABILITY IN PATIENTS WITH SUSPECTED PANCREATIC CANCER

    Nov 1, 2004, 00:00

  • PAR25 CROSS-VALIDATION OF A NEW QUESTIONNAIRE DESIGNED TO PREDICT FUTURE RISK OF NSAID-INDUCED GASTROINTESTINAL EVENTS

    Nov 1, 2004, 00:00

  • QL2 THE HEALTH RELATED QUALITY OF LIFE IN PARKINSONS DISEASE IN GERMANY

    Nov 1, 2004, 00:00

  • PCNI7 DOES GEMCITABINE PLUS CISPLATIN PROVIDE VALUE FOR MONEY IN THE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER IN THE UK?

    Nov 1, 2004, 00:00

  • PCVI7 COSTS OF HYPERTENSION IN POLAND MEASURED FROM THE THIRD PARTY PAYER PERSPECTIVE IN COMPARISON WITH THE SOCIETAL PERSPECTIVE

    Nov 1, 2004, 00:00

  • PCN7 THE LIFETIME COST OF GEFITINIB ('IRESSA') IN TREATING PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC)

    Nov 1, 2004, 00:00

  • PCN34 UTILITY ASSOCIATED WITH SEVERITY OF CANCER-RELATED ANAEMIA (CRA)- A SOCIETAL VALUATION

    Nov 1, 2004, 00:00

  • PCN22 A SYSTEMATIC EVALUATION OF THE IMPACT OF THE SCREENING INTERVAL ON EFFECTIVENESS AND COST-EFFECTIVENESS OF DIFFERENT CERVICAL CANCER SCREENING TECHNIQUES

    Nov 1, 2004, 00:00

  • PNL26 A NEW SCREENING TOOL FOR MIGRAINE IN THE GENERAL POPULATION- THE MIGRAINE-SCREEN-Q (MS-Q)

    Nov 1, 2004, 00:00

  • PGI4 USE OF CAPSULE ENDOSCOPY IN DIAGNOSING OBSCURE GASTROINTESTINAL BLEEDING- COST-EFFECTIVENESS EVALUATION FROM A EUROPEAN PERSPECTIVE

    Nov 1, 2004, 00:00

  • PCV36 ECONOMIC EVALUATION OF PRIMARY PREVENTION OF CVD EVENTS WITH STATINS IN ITALY

    Nov 1, 2004, 00:00

  • MC4 FLEXIBILITY AND TRANSPARENCY OF BAYESIAN NETWORKS- MODELING THE ECONOMIC IMPACT OF DRUG-ELUTING CORONARY STENTS

    Nov 1, 2004, 00:00

  • PIN23 PROSPECTIVE STUDY ON ACUTE LOWER RESPIRATORY TRACT INFECTION IN CHILDREN YOUNGER THAN 3 YEARS IN GERMANY (PRI.DE)-ECONOMIC IMPACT OF COMMUNITY-ACQUIRED CASES TREATED BY OFFICE-BASED PEDIATRICIANS (PRIMARY CARE)

    Nov 1, 2004, 00:00

  • PCV45 A SHORT-TERM RETROSPECTIVE ECONOMIC EVALUATION FOR THE TREATMENT OF MILD TO MODERATE ESSENTIAL HYPERTENSION WITH ANGIOTENSIN ll-ANTAGONISTS IN SPAIN

    Nov 1, 2004, 00:00

  • PCN3I EVALUATION OF PEMETREXED VERSUS DOCETAXEL IN THE SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER- PATIENT PREFERENCE AND WILLINGNESS-TO-PAYWITH DISCRETE CHOICE CONJOINT ANALYSIS

    Nov 1, 2004, 00:00

  • PRS4 COST OF TREATMENT AND REIMBURSEMENT OF HOSPITALIZED COMMUNITY-ACQUIRED PNEUMONIA WITH I.V. MOXIFLOXACIN COMPARED TO STANDARD ANTIBIOTIC TREAMENT IN GERMANY

    Nov 1, 2004, 00:00

  • PHP24 ANALYSIS OF 'INNOVATOR' DRUGS FINANCED BY SPANISH NATIONAL HEALTH SERVICE OVER THE PERIOD 1996-2003

    Nov 1, 2004, 00:00

  • PUK1 THE COST-EFFECTIVENESS OF EXTENDED RELEASE TOLTERODINE IN THE MANAGEMENT OF OVERACTIVE BLADDER IN GERMANY AND THE UNITED KINGDOM

    Nov 1, 2004, 00:00

  • PDB28 VALIDATION OF ORAL ANTIDIABETIC DRUGS PRESCRIPTIONS- THE VIEWS OF PRIMARY CARE PHYSICIANS

    Nov 1, 2004, 00:00

  • PDB12 COSTS OF TYPE-2 DIABETES MELLITUS- A COMPARISON BETWEEN DIABETIC AND NON-DIABETIC SUBJECTS

    Nov 1, 2004, 00:00

  • PHP26 PHYSICIANSACTIVITY HETEROGENEITY- AN EMPIRICAL STUDY IN TWO FRENCH REGIONS

    Nov 1, 2004, 00:00

  • PCV52 VALIDATION OF THE CAMBRIDGE PULMONARY HYPERTENSION OUTCOME REVIEW (CAMPHOR) QUESTIONNAIRE

    Nov 1, 2004, 00:00

  • PCV72 CHOLESTEROL GOAL ATTAINMENT AMONG PATIENTS TREATED WITH LIPID LOWERING DRUGS IN HUNGARY

    Nov 1, 2004, 00:00

  • PPN1 ESTIMATING THE INCIDENCE AND COSTS OF TREATING ADVERSE EVENTS IN PATIENTS TREATED WITH STRONG OPIOIDS FOR CHRONIC NON-MALIGNANT PAIN

    Nov 1, 2004, 00:00

  • PCVI9 COST-EFFECTIVENESS ANALYSIS OF THE MANAGEMENT OF ARTERIAL HYPERTENSION

    Nov 1, 2004, 00:00

  • PHP15 PREFERENCES MATTER- UNDERSTANDING DEMAND FOR VOLUNTARY HEALTH INSURANCE

    Nov 1, 2004, 00:00

  • PCN38 THE IMPACT OF SCREENING ADHERENCE ON MEDICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING IN GERMANY-A DECISION ANALYSIS

    Nov 1, 2004, 00:00

  • PCN42 POOLING CLINICAL AND COST OUTCOMES- A CASE STUDY OF BEST SUPPORTIVE CARE (BSC) IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC)

    Nov 1, 2004, 00:00

  • EE3 COST-EFFECTIVENESS OF TREATMENT FOR MODERATE-TO-SEVERE PSORIASIS

    Nov 1, 2004, 00:00

  • PDB32 LONG-TERM DIABETES COMPLICATIONS- INFLUENCE OF DELAY IN STARTING INTENSIFIED THERAPY AND OF PATIENT RATES TREATED TO TARGET A1C.ANALYSES WITH THE DIABETES MELLITUS MODEL (DMM)

    Nov 1, 2004, 00:00

  • PMH22 INCIDENCE, PREVALENCE AND TREATMENT PATTERNS OF PATIENTS WITH ADHD SYMPTOMS IN THE NETHERLANDS

    Nov 1, 2004, 00:00

  • PNL1 PREVALENCE, HEALTH RESOURCES USAGE AND COST OF VASCULAR DEMENTIA IN COMPARISON WITH ALZHEIMER DISEASE IN A POPULATION SETTING IN SPAIN

    Nov 1, 2004, 00:00

  • PCV5 LONG-TERM COST-EFFECTIVENESS OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT ST-SEGMENT ELEVATION IN GERMANY

    Nov 1, 2004, 00:00

  • PGI8 PHARMACOECONOMIC ASPECTS OF CROHNS DISEASE IN SLOVAKIA

    Nov 1, 2004, 00:00

  • PBR5 COST-EFFECTIVENESS OF EXTENDED VENOUS THROMBOEMBOLISM PROPHYLAXIS WITH FONDAPARINUX IN MAJOR ORTHOPAEDIC SURGERY IN SWITZERLAND

    Nov 1, 2004, 00:00

  • PDB25 QUALITY OF LIFE IN SUBJECTS WITH AND WITHOUT TYPE-2 DIABETES MELLITUS

    Nov 1, 2004, 00:00

  • QL1 AGREEMENT BETWEEN PATIENTS- REPORTED OUTCOMES IN LIPODYSTROPHY (HIV/AIDS)

    Nov 1, 2004, 00:00

  • PRS7 THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE HAS A NEGATIVE IMPACT ON THE QUALITY OF LIFE OF THE PATIENT- THE RESULTS OF THE EPIDEPOC STUDY

    Nov 1, 2004, 00:00

  • HPI THE RELATIONSHIP BETWEEN HEALTH INSURANCE TYPE AND COSTS OF PRESCRIBED DRUGS

    Nov 1, 2004, 00:00

  • PCNI6 COMPARATIVE COSTS OF GEMCITABINE/CISPLATIN, PACLITAXEL/CARBOPLATIN AND VINORELBINE/CISPLATIN IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN GERMANY

    Nov 1, 2004, 00:00

  • PCN9 ATIME-IN-MOTION STUDY OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID FOR THE TREATMENT OF METASTATIC BONE DISEASE IN BREAST CANCER PATIENTS IN THE UK

    Nov 1, 2004, 00:00

  • PHP2 IMPACT OF PRESCRIBING GUIDELINES FOR INPATIENT ANTICOAGULATION

    Nov 1, 2004, 00:00

  • PGI14 COST-EFFECTIVENESS EVALUATION FOR A NEW DIAGNOSTIC TEST CONSIDERING ALSO COSTS FOR FALSE NEGATIVE AND FALSE POSITIVE DIAGNOSES AT VARIOUS PREVALENCE RATES

    Nov 1, 2004, 00:00

  • PCV73 COSTS ASSOCIATED WITH ALTERNATIVE FETAL CARDIOLOGY REFERRAL MODES- APPLICATION OF PROPENSITY SCORE MATCHING

    Nov 1, 2004, 00:00

  • PMW2 HOW MUCH DOES UNINTENDED PREGNANCY COST THE UK HEALTH CARE SYSTEM?

    Nov 1, 2004, 00:00

  • PMH18 ASSESSING THE TOTAL COST OF CARE FOR CEREBRAL PALSY PATIENTS WHO USE BOTULINUM TOXIN TYPE A- AN APPROACH TO CONTROLLING BIAS IN CASE CONTROL STUDIES

    Nov 1, 2004, 00:00

  • PCV24 PHARMACOECONOMIC EVALUATION OF THE CIBIS-II TRIAL

    Nov 1, 2004, 00:00

  • PNL28 CENTERED REGRESSION FUNCTIONS AS A TECHNIQUE TO IMPROVE FLEXIBILITY AND TRANSFERABILITY OF MARKOV MODELS

    Nov 1, 2004, 00:00

  • PIN17 THE COSTS OF SEVERE SEPSIS MANAGEMENT IN INTENSIVE CARE UNITS IN POLAND

    Nov 1, 2004, 00:00

  • PUK3 ECONOMIC ASSESSMENT OF URO-VAXOM IN FEMALE PATIENTS WITH RECURRENT URINARY TRACT INFECTION IN GERMANY

    Nov 1, 2004, 00:00

  • PCV7 THE COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION IN POLAND

    Nov 1, 2004, 00:00

  • PCV53 TRENDS IN PREVALENCE, AWARENESS, TREATMENT.AND CONTROL OF HYPERTENSION AMONG CHINESE AMERICANS FROM 2001 THROUGH 2004

    Nov 1, 2004, 00:00

  • PUK9 EVALUATION OF THE COST UTILITY OF SIROLIMUS VERSUS TACROLIMUS FOR IMMUNOSUPPRESSION FOR RENAL TRANSPLANTATION IN THE UNITED KINGDOM

    Nov 1, 2004, 00:00

  • PMC9 HEALTH PROGRAM IMPACT EVALUATION USING OBSERVED AND EXPECTED TIME SERIES OF PHARMACEUTICAL CONSUMPTIONS

    Nov 1, 2004, 00:00

  • PIN22 MODELLING THE COST-EFFECTIVENESS OF ACTIVATED PROTEIN C (XIGRIS) TREATMENT OF SEPTIC PATIENTS ININTENSIVE CARE UNITS IN HUNGARY

    Nov 1, 2004, 00:00

  • PCV43 THE IMPACT OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) ENOXAPARIN USAGE ON OUTCOMES OF TREATMENT MANAGEMENT OF PATIENTS WITH ACUTE CORONARY SYNDROMES (ACS) IN RUSSIA

    Nov 1, 2004, 00:00

  • NPI HEALTH-RELATED QUALITY OF LIFE IN NEUROMUSCULAR DISEASES

    Nov 1, 2004, 00:00

  • PCN40 DISPARITIES IN MEDICAID CANCER EXPENDITURES

    Nov 1, 2004, 00:00

  • PPN5 PROSPECTIVE ASSESSMENT OF THE HEALTH AND ECONOMIC BURDEN OF NEUROPATHIC PAIN

    Nov 1, 2004, 00:00

  • NP4 12-MONTHS COSTS OF PARKINSONS DISEASE IN GERMANY-RESULTS OF A PROSPECTIVE STUDY

    Nov 1, 2004, 00:00

  • PES17 LIVING WITH A DERMATOSIS- A NATIONAL SURVEY OF QUALITY OF LIFE IN BELGIUM

    Nov 1, 2004, 00:00

  • PMH1 IMPACT OF WEIGHT GAIN ON TREATMENT EFFECTIVENESS WITH OLANZAPINE OR ARIPIPRAZOLE, CONSIDERING NONADHERENCE, RELAPSE AND COST OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA IN FINLAND

    Nov 1, 2004, 00:00

  • PMC21 AN EXPLORATION OF THE DISCREPANCIES BETWEEN HEALTH STATE VALUATIONS OF PATIENTS AND THE GENERAL POPULATION

    Nov 1, 2004, 00:00

  • PHP36 REIMBURSMENT POLICY IN TURKEY- NEW CONSENSUS

    Nov 1, 2004, 00:00

  • PBR12 CLINICAL AND SOCIO-DEMOGRAPHIC CHARACTERISTICS INFLUENCE PATIENTS PREFERENCES TOWARDS HEMOPHILIA TREATMENT

    Nov 1, 2004, 00:00

  • PGI13 EFFECT OF TEGASEROD IN WOMEN WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN SOUTH AFRICA

    Nov 1, 2004, 00:00

  • PBR1 COST OF KALIUM SUPPLEMENTATION WITH KALIPOZ PROLONGATUM OR KALDYUM FROM PAYER PERSPECTIVE IN POLAND

    Nov 1, 2004, 00:00

  • HP6 MODELLING USE OF HOSPITAL SERVICES AS A FUNCTION OF NEEDS AND SUPPLY IN ITALY

    Nov 1, 2004, 00:00

  • PES20 SUNBURNS AND QUALITY OF LIFE

    Nov 1, 2004, 00:00

  • PNL9 INDIRECT COSTS ASSOCIATED TO INSOMNIA IN OCCUPATIONAL HEALTH- THE SISYPHE STUDY

    Nov 1, 2004, 00:00

  • PMH25 EMERGENCY DEPARTMENTS-THE FRONT LINE OF SCHIZOPHRENIA MANAGEMENT?

    Nov 1, 2004, 00:00

  • PUK2 COST-EFFECTIVENESS ANALYSIS OF EXTENDED-RELEASE TOLTERODINE VERSUS IMMEDIATE-RELEASE TOLTERODINE IN THE MANAGEMENT OF OVERACTIVE BLADDER IN SPAIN

    Nov 1, 2004, 00:00

  • PNL29 ESTIMATING THE COST OF ILLNESS IN EUROPE-A MODEL WITH MULTIPLE SCLEROSIS AS AN EXAMPLE

    Nov 1, 2004, 00:00

  • PMH19 THE PERCEIVED BENEFITS OF DOSING SCHEDULES FOR CHILDREN WITH ADHD

    Nov 1, 2004, 00:00

  • PES2 ASSOCIATION BETWEEN MORTALITY AND VISUAL IMPAIRMENT ESTIMATED FROM A FRENCH NATIONAL SURVEY

    Nov 1, 2004, 00:00

  • PNL12 HEALTHCARE UTILIZATION AND SOCIOECONOMIC ASPECTS OF NEUROMUSCULAR DISEASES

    Nov 1, 2004, 00:00

  • PCN25 COST-EFFECTIVENESS-ANALYSIS OF THE THERAPY OF STAGETI-T2 PROSTATE CANCER WITH PERMANENT SEED IMPLANTATION IN COMPARISON WITH RADICAL PROSTATECTOMY

    Nov 1, 2004, 00:00

  • PDB33 EAGLE-DIABETES MODEL- BASIC FEATURES AND INTERNAL VALIDATION OF SIMULATING LONG-TERM DIABETIC OUTCOMES AND RELATED COSTS

    Nov 1, 2004, 00:00

  • PDB6 THE COST OF TYPE-2 DIABETES IN UKRAINE

    Nov 1, 2004, 00:00

  • PDB9 THE VALUE OF ORAL MONOTHERAPY ALTERNATIVES IN THE FIRST-LINE TREATMENT OF TYPE-2 DIABETES MELLITUS

    Nov 1, 2004, 00:00

  • PDB11 PHARMACOECONOMIC ASPECTS OF USE OF INSULIN GLARGINE IN TREATMENT OF DIABETES MELLITUS TYPE 2 (DM T2) IN RUSSIA

    Nov 1, 2004, 00:00

  • PMC16 VISUAL ANALOGUE SCALES- ARE THE ELICITED PREFERENCES ANALOGUE?

    Nov 1, 2004, 00:00

  • PAA9 FROM SF-36TO UTILITY SCORES- A COMPARISON OF DIFFERENT ALGORITHMS IN DIFFERENT SETTINGS

    Nov 1, 2004, 00:00

  • PAR27 ASSESMENT OF QUALITY OF LIFE (QOL) IN ADULTS WITH JUVENILE IDIOPATIC ARTHRITIS (Alj) DIAGNOSIS IN MEXICO- THE DISABILITY IMPACT

    Nov 1, 2004, 00:00

  • PCV5I CHRONIC VENOUS DISEASE AND HEALTH STATUS

    Nov 1, 2004, 00:00

  • HP8 EXPLAINING THE LACK OF SUCCESS OF GENERIC DRUGS IN BELGIUM- A POLICY PERSPECTIVE

    Nov 1, 2004, 00:00

  • PCV75 THE APPLICATION OF TWO ANALYTIC METHODS TO INVESTIGATE THE INFLUENCE OF POOR INR CONTROL ON RISKS OF HOSPITALISATION FOR PATIENTS RECEIVING WARFARIN

    Nov 1, 2004, 00:00

  • PCN3 COST-EFFECTIVENESS OF BORTEZOMIB (VELCADE) FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA

    Nov 1, 2004, 00:00

  • MC3 QALYS LACK QUALITY IN PAEDIATRIC CARE-A CRITICAL REVIEW OF PUBLISHED COST-UTILITY STUDIES IN CHILD HEALTH

    Nov 1, 2004, 00:00

  • PAR6 ECONOMIC EVALUATION OF THERAPY WITH NSAIDAND WITH COX-2 IN SUBJECTS AGED 66 YEARS OR MORE

    Nov 1, 2004, 00:00

  • PBR10 ESTABLISHING HEMOPHILIA PATIENTS PREFERENCES IN PROPHYLAXIS- A CONJOINT ANALYSIS PILOT STUDY

    Nov 1, 2004, 00:00

  • PCV62 HYPERTENSION CLINIC AND HYPERTENSION SPECIALIST IS A COST-EFFECTIVE TOOL FOR THE DISEASE CONTROL IMPROVEMENT IN BELARUS

    Nov 1, 2004, 00:00

  • PMC17 THERES NO F IN UTILITY

    Nov 1, 2004, 00:00

  • PCV40 COSTS OF ISCHEMIC STROKE TREATMENT IN RUSSIAN FEDERATION

    Nov 1, 2004, 00:00

  • PIN1 CLINICAL PRACTICE GUIDELINE EVALUATION- NEONATAL INFECTION WITH MATERNAL HISTORY OF PREMATURE RUPTURE OF MEMBRANE (PROM)

    Nov 1, 2004, 00:00

  • PRS1 EVALUATION OF MONOTHERAPY AND COMBINATION ANTIBIOTIC TREATMENT REGIMENS FOR PSEUDOMONAS AERUGINOSA PNEUMONIA

    Nov 1, 2004, 00:00

  • PNL23 CHRONIC NEUROPATHIC PAIN (NEP) IMPACT ON PATIENT QUALITY OF LIFE AND DISABILITY- RESULTS FROM THE DONEGA STUDY

    Nov 1, 2004, 00:00

  • PNL6 THE HOSPITAL COSTS OF PRIMARY STROKE PATIENTS MANAGEMENT IN POLAND

    Nov 1, 2004, 00:00

  • PAR 13 COST-EFFECTIVENESS OFVALDECOXIB COMPARED TO DICLOFENAC IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN THE UK (UK) AND GERMANY

    Nov 1, 2004, 00:00

  • PIN32 THE COST OF ANTIBIOTIC THERAPY IN PATIENTS UNDERGOING SURGERY FOR COLORECTAL CANCER

    Nov 1, 2004, 00:00

  • PMC3 ECONOMIC EVALUATION IN LATIN AMERICA

    Nov 1, 2004, 00:00

  • PHP33 SATISFACTION AMONG GERMAN PHYSICIANS-A REPRESENTATIVE EMPIRICAL STUDY

    Nov 1, 2004, 00:00

  • MC7 USING STATED RISK-BENEFIT TRADEOFF PREFERENCES TO IDENTIFY POTENTIAL THERAPEUTIC RISK-MANAGEMENT PROBLEMS

    Nov 1, 2004, 00:00

  • PDB21 ECONOMIC VALUE OF ACARBOSE TREATMENT IN PERSONS WITH IMPAIRED GLUCOSE TOLERANCE (IGT) FOR THE GERMAN HEALTH CARE SYSTEM

    Nov 1, 2004, 00:00

  • PUK6 COST OF RENAL TRANSPLANTATION IN BELGIUM

    Nov 1, 2004, 00:00

  • PAR 10 PATTERNS OF DOSING WITH ADALIMUMAB AMONG COMMERCIALLY INSURED PATIENTS

    Nov 1, 2004, 00:00

  • PMH21 IS HEALTH-RELATED QUALITY OF LIFE EVALUATION DIFFERENT BETWEEN CLINICAL TRIALS AND OBSERVATIONAL STUDIES IN MAJOR DEPRESSIVE DISORDER?

    Nov 1, 2004, 00:00

  • Author Index, Volume 7

    Nov 1, 2004, 00:00

  • PCN36 THE VALUE OF THE USE OF ANASTROZOLE AS AN ALTERNATIVE ADJUVANT THERAPY FOR EARLY BREAST CANCER (EBC) USING DISCRETE CHOICE WILLINGNESS-TO-PAY (WTP) METHODOLOGY

    Nov 1, 2004, 00:00

  • PMW1 ECONOMIC EVALUATION OF THE ADMINISTRATION OF FOLLITROPIN- WITH A PEN DEVICE COMPARED WITH ADMINISTRATION OF MENOTROPIN BY CONVENTIONAL SYRINGE

    Nov 1, 2004, 00:00

  • PNL25 INTERNAL, EXTERNAL, AND CROSS-MODEL VALIDATION OF A MULTI-OUTCOME DECISION MODEL FOR PARKINSONS DISEASE

    Nov 1, 2004, 00:00

  • PHP39 SELF-EFFICACY AND ACADEMIC ACHIEVEMENT OF THE FIFTH YEAR PHARMACY STUDENTS OF CHULALONGKORN UNIVERSITY, 2003

    Nov 1, 2004, 00:00

  • PPN4 COST-EFFECTIVENESS OF THE COMBINATION TRAMADOL PLUS PARACETAMOL IN TREATMENT OF SUBACUTE LOW BACK PAIN IN A DUTCH HEALTH CARE SETTING

    Nov 1, 2004, 00:00

  • PCV2 ACHIEVEMENT OF THE EUROPEAN 1998 LDL-C GOAL BY HYPERCHOLESTEROLAEMIC PATIENTS IN THE STELLAR TRIAL- AN EVIDENCE-BASED MEDICINE (EBM) APPROACH

    Nov 1, 2004, 00:00

  • PCV44 VKATREATMENT RELATED COSTS IN FRANCE IN PATIENTS WITH CHRONIC NONVALVULAR ATRIAL FIBRILLATION- COST DATA FROM THE INTERNATIONAL STUDY OF ANTICOAGULATION MANAGEMENT (ISAM)

    Nov 1, 2004, 00:00

  • PUK13 LOWER MENTAL HEALTH SCORES MEASURED USING THE SF-36 HEALTH SURVEY IS AN INDEPENDENT PREDICTOR OF MORTALITY IN YOUNGER PATIENTS RENAL REPLACEMENT THERAPY

    Nov 1, 2004, 00:00

  • PAR14 COSTS OF RA IN GERMANY ON A MICRO-COSTING LEVEL

    Nov 1, 2004, 00:00

  • PMH4 THE COST OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER IN AUSTRALIA; A RETROSPECTIVE AUDIT

    Nov 1, 2004, 00:00

  • PHP13 THE HOSPITAL DIAGNOSTIC THERAPEUTIC PATHWAY OF PATIENTS AFFECTED BY CRITICAL ISCHEMIA OF THE LOWER LIMBS WHICH IS UNRESPONSIVE TO REVASCULARIZATION

    Nov 1, 2004, 00:00

  • PES1 ASSOCIATION BETWEEN DIMINISHED ACTIVITY OF DAILY LIVING AND VISUAL IMPAIRMENT IN SUBJECTS LIVING IN THE COMMUNITY- RESULTS FROM A FRENCH NATIONAL SURVEY

    Nov 1, 2004, 00:00

  • PCN32 INSTRUMENTS TO MEASURE PATIENT-REPORTED OUTCOMES AND PERCEPTIONS OF CANCER-RELATED FATIGUE- A REVIEW OF THE LITERATURE

    Nov 1, 2004, 00:00

  • PAR11 A COST EFFICACY ANALYSIS ON ANTI-TNF THERAPY IN ANKYLOSING SPONDYLITIS

    Nov 1, 2004, 00:00

  • CS4 ANTIPSYCHOTIC PATTERNS AND TREATMENT COST IN FRANCE

    Nov 1, 2004, 00:00

  • PUK18 VALIDATION OF A PATIENT-ADMINISTERED QUESTIONNAIRE TO MEASURE ACTIVITY IMPAIRMENT AS A RESULT OF UNCOMPLICATED URINARY TRACT INFECTION- THE ACTIVITY IMPAIRMENT ASSESSMENT (AIA)

    Nov 1, 2004, 00:00

  • PAR2I CROSS-SURVEY OF RHEUMATOLOGISTS AND GP AWARENESS AND KNOWLEDGE OF FIBROMYALGIA

    Nov 1, 2004, 00:00

  • PCV66 POOLED EFFICACY OF DISEASE MANAGEMENT PROGRAMS IN PATIENTS WITH CONGESTIVE HEART FAILURE-A SYSTEMATIC REVIEW

    Nov 1, 2004, 00:00

  • CSI TEGASEROD IS COST-EFFECTIVE IN THE TREATMENT OF PATIENTS WITH IBS- AN ECONOMIC ANALYSIS OF THE TENOR (TEGASEROD IN NORDIC COUNTRIES) STUDY

    Nov 1, 2004, 00:00

  • PES24 IMPACTED CERUMEN- A LITERATURE REVIEW

    Nov 1, 2004, 00:00

  • PNL18 COSTS AND OUTCOMES ASSOCIATED WITH THE USE OF BOTULINUM TOXIN TYPE A (BTX-A) IN THE TREATMENT OF FLEXED WRIST/CLENCHED FIST POST-STROKE SPASTICITY

    Nov 1, 2004, 00:00

  • PCN8 COST-EFFECTIVENESS ANALYSIS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID OR IV GENERIC PAMIDRONATE FOR BONE METASTASES FROM BREAST CANCER IN PATIENTS RECEIVING ORAL HORMONAL THERAPY IN THE UK

    Nov 1, 2004, 00:00

  • PDB13 ECONOMIC EVALUATION OF THE STEPPED VERSUS ORDINARY CARE FOR PREVENTION OF TYPE-2 DIABETES IN THE JDPP- JAPAN DIABETES PREVENTION PROGRAM

    Nov 1, 2004, 00:00

  • PIN28 ASSESSMENT OF BODY CHANGES AND DISTRESS (ABCD) LIPODYSTROPHY QUESTIONNAIRE- CULTURAL ADAPTATION AND PSYCHOMETRIC VALIDATION IN FRENCH

    Nov 1, 2004, 00:00

  • PHP29 PATHOLOGY RELATED DIFFERENCES INVARIANCE OF DRUG INSURANCE COST IN HOSPITAL STAYS- FEASIBILITY OF FIXED FUNDING IN PATHOLOGIES WITH REDUCED COST VARIANCE

    Nov 1, 2004, 00:00

  • PAR9 A COST MINIMISATION ANALYSE FOR STUDYING THE EFFICIENCY OF BIOLOGIC THERAPIES (BT) IN RHEUMATOID ARTHRITIS (RA). OVERVIEW FOR THE SPANISH SETTING

    Nov 1, 2004, 00:00

  • DB3 DECREASED RATES OF MAJOR HYPOGLYCAEMIC EVENTS LEAD TO IMPROVED LONG TERM COST EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30/70 VERSUS BIPHASIC HUMAN INSULIN 30 IN TYPE 2 DIABETIC SUBJECTS IN DANISH, FINNISH, GERMAN, NORWEGIAN, SPANISH, SW ...

    Nov 1, 2004, 00:00

  • POS6 COST-EFFECTIVENESS OF MIACALCIC IN TREATMENT OF PAIN DUE TO OSTEOPOROTIC VERTEBRAL FRACTURE

    Nov 1, 2004, 00:00

  • PCN6 HOSPITALIZARON COSTS OF PATIENTS WITH INFECTIONS WHO HAVE LUNG CANCER OR NEUTROPENIA IN SWEDEN-A RETROSPECTIVE DATABASE STUDY

    Nov 1, 2004, 00:00

  • HP3 PHARMACOECONOMIC EDUCATION AT NON-US COLLEGES OF PHARMACY

    Nov 1, 2004, 00:00

  • PES13 A COST MINIMISATION ANALYSIS OF CUSTOM PAK FOR CATARACT SURGERY

    Nov 1, 2004, 00:00

  • PMW4 VALIDATION OF THE SPANISH VERSION OF THE SELFESTEEM AND RELATIONSHIP (SEAR) QUESTIONNAIRE FOR MEN WITH ERECTILE DYSFUNCTION (ED)

    Nov 1, 2004, 00:00

  • PAR7 FIBROMYALGIA COST OF CARE

    Nov 1, 2004, 00:00

  • PCV2I ECONOMIC EVALUATION OF VARIOUS ANTIHYPERTENSIVE MONOTHERAPIES IN GREECE

    Nov 1, 2004, 00:00

  • MH4 ADHD-RELATED PATIENT AND FAMILY BURDEN- BASELINE RESULTS FROM THE OBSERVATIONAL STUDY ADORE IN GERMANY

    Nov 1, 2004, 00:00

  • PMH14 THE HEATLH-RELATED QUALITY OF LIFE OF CHILDREN SUFFERING FROM ADHD AND THE COSTS TO SOCIETY

    Nov 1, 2004, 00:00

  • PES15 IMPACT OF ATOPIC DERMATITIS ON PARENTS QUALITY OF LIFE AND USE OF DIRECT RESOURCES IN PATIENTS BETWEEN 2 AND 12 YEARS OLD. DAES STUDY

    Nov 1, 2004, 00:00

  • PAR 12 HOW ADEQUATE DO RA-PATIENTS REPORT INDIRECT COSTS?-THE EXAMPLE OF A GERMAN COHORT

    Nov 1, 2004, 00:00

  • PAR 19 SURVEY OF GLOBAL FIBROMYALGIA MANAGEMENT BY FRENCH RHEUMATOLOGISTS IN 2003

    Nov 1, 2004, 00:00

  • PGI9 IS HELICOBACTER PYLORI 'TEST AND TREAT' A COSTEFFECTIVE MANAGEMENT APPROACH FOR PATIENTS WITH TYPICAL REFLUX SYMPTOMS IN A POPULATION WITH A HIGH PREVALENCE OF H. PYLORI INFECTION

    Nov 1, 2004, 00:00

  • PPT2 THE DEFICIT IN HEALTH-RELATED QUALITY OF LIFE (HRQOL) FOR GROWTH HORMONE DEFICIENT (GHD) PATIENTS IN SPAIN AND ENGLAND WALES- A COMPARISON WITH NORMATIVE POPULATION DATA

    Nov 1, 2004, 00:00

  • PCN29 PROSTATE CANCER SPECIFIC SYMPTOMS IN A GERMAN REFERENCE POPULATION

    Nov 1, 2004, 00:00

  • PIN6 CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF ANTIVIRAL COMBINATION THERAPY WITH PEGINTERFERON ALFA-2B AND RIBAVIRIN FOR CHRONIC HEPATITIS C ADMINISTERED ACCORDING TO THE NEW GENOTYPESPECIFIC GUIDELINES

    Nov 1, 2004, 00:00

  • PCV65 PERSISTENCE WITH DIFFERENT FORMULATIONS OF THE ANTIHYPERTENSIVE DRUG NIFEDIPINE

    Nov 1, 2004, 00:00

  • PRS5 COSTS OF COMMUNITY-ACQUIRED PNEUMONIA FROM THE HOSPITALS PERSPECTIVE IN GERMANY-FINAL RESULTS OF A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2004, 00:00

  • PCV46 SCREENING FOR ABDOMINAL AORTIC ANEURYSM IN MEN. AN ECONOMIC EVALUATION BASED ON A SYSTEMATIC REVIEW OF THE LITERATURE

    Nov 1, 2004, 00:00

  • PCN2I A PHARMACOECONOMIC MODEL OF THE COST-EFFECTIVENESS OF GEFITINIB ('IRESSA') COMPARED WITH BEST SUPPORTIVE CARE (BSC) IN THIRD-LINE TREATMENT OF PATIENTS WITH REFRACTORY ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) IN THE UK

    Nov 1, 2004, 00:00

  • PRS8 IMPACT ON USE AND COST OF MEDICINES OF EXPANDED DRUG COVERAGE VIA POSITIVE LIST IN THE PHILIPPINES

    Nov 1, 2004, 00:00

  • PHP20 PROPER DRUG MANAGEMENT IN PHARMACY-THE ROLE OF PHARMACOECONOMICSAS PERCEIVED BY POLISH PHARMACISTS

    Nov 1, 2004, 00:00

  • PCVI3 ECONOMIC ASSESSMENT OF EZETIMIBE CO-ADMINISTRATION IN A HUNGARIAN CHD PATIENT COHORT NOTAT CHOLESTEROL GOAL ON SIMVASTATIN MONOTHERAPY

    Nov 1, 2004, 00:00

  • PC VI THE COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE TYPE 2 DIABETIC PATIENTS WITH MICROALBUMINURIA IN TAIWAN

    Nov 1, 2004, 00:00

  • PAR 15 A COMPARISON OF COST OF INFLIXIMAB AND ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN ITALY- RESULTS OF THE IERI STUDY GROUP

    Nov 1, 2004, 00:00

  • PIN12 COST-EFFECTIVENESS OF UNIVERSAL PNEUMOCOCCAL VACCINATION FOR INFANTS IN ITALY

    Nov 1, 2004, 00:00

  • PBR8 PHYSICIANS PREFERENCES FOR HEMOPHILIA TREATMENT EVALUATED BY CONJOINT ANALYSIS

    Nov 1, 2004, 00:00

  • QL5 VALIDATION OF THE GERMAN PROSTATE SPECIFIC MODULE (PSM)

    Nov 1, 2004, 00:00

  • PIN14 CALCULATING THE COST OF WOUND CARE IN A COMMUNITY SETTING IN THE UK- AN EXAMPLE USING MODERN WOUND MANAGEMENT DRESSINGS

    Nov 1, 2004, 00:00

  • CN4 COST-EFFECTIVENESS OF SAMARIUM-153-EDTMP COMPARED TO CONVENTIONAL PAIN THERAPY IN GERMANY

    Nov 1, 2004, 00:00

  • PDB18 SEARCHING FOR DIABETES MELLITUS (DM) IN PRIMARY CARE-IT IS GOOD VALUE-FOR-MONEY IN POLAND? (COST OF DIAGNOSING DIABETES MELLITUS IN PRIMARY CARE CONDITION IN POLAND)

    Nov 1, 2004, 00:00

  • PGI6 ECONOMIC EVALUATION OF RABEPRAZOLE VS. OMEPRAZOLE IN THE CURATIVE TREATMENT OF REFLUX OESOPHAGITIS

    Nov 1, 2004, 00:00

  • PPN6 BURDEN OF ILLNESS SURVEY IN PATIENTS WITH PAINFUL NEUROPATHIC DISORDER (PNDS) IN GERMANY

    Nov 1, 2004, 00:00

  • PIN9 COMPARING COSTS AND EFFECTIVENESS OF HAART TIMING IN HIV INFECTION- EVIDENCE FROM THE I.CO.N.A. COHORT (ON BEHALF OF THE I.CO.N.A. STUDY GROUP)

    Nov 1, 2004, 00:00

  • PMC13 DEVELOPING THE EUROPEAN NETWORK OF HEALTH ECONOMIC EVALUATIONS DATABASES (EURONHEED)- THE ACTIVITIES OF ONE CENTRE TO FULFILL BOTH INTERNATIONAL AND LOCAL NEEDS

    Nov 1, 2004, 00:00

  • PUK15 PATIENTS UNDERGOING PERITONEAL DILISIS HAVE BETTER PERCEIVED HEALTH IN SEVERAL SPECIFIC PROBLEMS RELATED WITH RENAL DISEASE THAN PATIENTS UNDERGOING HEMODIALYSIS

    Nov 1, 2004, 00:00

  • CV4 EVALUATION OF SURVIVAL AND ISCHAEMIC AND THROMBOEMBOLIC EVENT RATES IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN THE GENERAL POPULATION WHEN TREATED AND UNTREATED WITH WARFARIN

    Nov 1, 2004, 00:00

  • PNL3 PREDICTORS FOR DIRECT AND INDIRECT COSTS IN PARKINSONS DISEASE

    Nov 1, 2004, 00:00

  • NP2 COST ASSOCIATED WITH PERSISTENCY AMONG PATIENTS WITH PARTIAL SEIZURE DISORDER SWITCHING TO OXCARBAZEPINE MONOTHERAPY

    Nov 1, 2004, 00:00

  • PMH12 THE IMPACT OF PREMATURE DISCONTINUATION OF ANTIDEPRESSANT THERAPY IN MAJOR DEPRESSIVE DISORDER IN THE UK

    Nov 1, 2004, 00:00

  • PNL19 VALIDATING THE RESTLESS LEGS SYNDROME QUALITY OF LIFE QUESTIONNAIRE (RLSQOL) IN A TRIAL PATIENT POPULATION

    Nov 1, 2004, 00:00

  • PNL14 THE COST-EFFECTIVENESS OF TREATING PATIENTS WITH RESTLESS LEGS SYNDROME (RLS) USING ROPINIROLE

    Nov 1, 2004, 00:00

  • PDB17 ABSOLUTE AND INCREMENTAL EFFECTS OF THERAPYSWITCHING THRESHOLDS ON THE COST-EFFECTIVENESS OF TREATMENTS FOR OBESE TYPE-2 DIABETES PATIENTS IN GERMANY

    Nov 1, 2004, 00:00

  • PMC1 BOOTSTRAP CONFIDENCE INTERVALS FOR THE ANGULAR TRANSFORMED ICER- ARE MORE SOPHISTICATED METHODS THE BETTER CHOICE?

    Nov 1, 2004, 00:00

  • PMH20 PATIENT-REPORTED OUTCOMES- DO THEY AGREE WITH OBJECTIVE CAREGIVER-REPORTED OUTCOMES FOR INDIVIDUALS WITH SCHIZOPHRENIA RESIDING IN THE COMMUNITY?

    Nov 1, 2004, 00:00

  • PDB26 THE IMPACT OF VASCULAR EVENTS ON HEALTH-RELATED UTILITY IN PATIENTS WITH AND WITHOUT TYPE-2 DIABETES

    Nov 1, 2004, 00:00

  • PNL32 HEALTHCARE RESOURCES USED BY SPANISH PRIMARY CARE PHYSICIANS IN PATIENTS WITH SUBJECTIVE MEMORY COMPLAINTS OR COGNITIVE IMPAIRMENT.THE ISSEA STUDY

    Nov 1, 2004, 00:00

  • PES26 ANALYSIS OF RUSSIAN PHARMACEUTICAL MARKET OF ANTI-GLAUCOMA MEDICINES IN THE PERIOD 2000-2003

    Nov 1, 2004, 00:00

  • PPN11 DEVELOPMENT OF AN INSTRUMENT TO CAPTURE EASE-OFCARE OUTCOMES IN PATIENTS TREATED WITH PCA DELIVERY SYSTEMS

    Nov 1, 2004, 00:00

  • PCV34 COST-EFFECTIVENESS OF ANTICOAGULATION WITH BIVALIRUDIN VS. HEPARIN AND GLYCOPROTEIN INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN SWEDEN

    Nov 1, 2004, 00:00

  • PCNII COST-EFFECTIVENESS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID OR IV PAMIDRONATE IN THE TREATMENT OF BREAST CANCERWITH BONE METASTASES IN PATIENTS UNDERGOING IV CHEMOTHERAPY IN THE UK

    Nov 1, 2004, 00:00

  • PGI3 COST-EFFECTIVENESS OF ESOMEPRAZOLE COMPARED TO PANTOPRAZOLE AND GENERIC OMEPRAZOLE IN ENDOSCOPY POSITIVE GERD PATIENTS IN GERMANY

    Nov 1, 2004, 00:00

  • NP3 A COST-UTILITY MODEL OF TREATMENT OF NEWLY DIAGNOSED EPILEPSY IN GERMANY COMPARING TOPIRAMATE, CARBAMAZEPINE AND VALPROATE

    Nov 1, 2004, 00:00

  • PAA4 A COMPARATIVE ANALYSIS OF EFFICACY, SAFETY AND COST-EFFECTIVENESS OF SALMETEROL AND MONTELUCAST IN THERAPY OF BRONCHIAL ASTHMA

    Nov 1, 2004, 00:00

  • PCV63 OVER-ADHERENCE WITH ANTIHYPERTENSIVE MEDICATIONS AMONG CENTRAL TEXAS VETERANS

    Nov 1, 2004, 00:00

  • DB4 PROOF OF CONCEPT OF A WIRELESS APPROACH FOR ENABLING COMMUNICATIONS BETWEEN GERMAN PHYSICIANS AND THEIR PATIENTS WITH TYPE 2 DIABETES TREATED WITH NATEGLINIDE

    Nov 1, 2004, 00:00

  • PCV61 THE USE OF INTERNET-BASEDTECHNOLOGYTO ASSESS MEDICATION ADHERENCE IN PATIENTS WITH HYPERTENSION AND TO PROVIDE INTERACTIVE HEALTH INFORMATION

    Nov 1, 2004, 00:00

  • PES9 PREVALENCE OF FRACTURES AND DEPRESSION AND THEIR ASSOCIATION WITH BLINDNESS IN A MEDICARE POPULATION WITH PRIMARY OPEN-ANGLE GLAUCOMA- AN EXAMINATION OF BLINDNESS-RELATED COMORBIDITIES AND THEIR COSTS

    Nov 1, 2004, 00:00

  • PMH26 SSRI UTILIZATION AND PERSISTENCE IN A CALIFORNIA MEDICAID POPULATION

    Nov 1, 2004, 00:00

  • PNL24 COMPARING CLASSIFICATION AND REGRESSION TREE ANALYSIS WITH MULTIPLE REGRESSION FOR TRANSLATING A CLINICAL PARKINSONS DISEASE SCALE INTO UTILITIES

    Nov 1, 2004, 00:00

  • PHP27 AGE AND GENDER DISTRIBUTION OF PHARMACEUTICAL EXPENDITURE PER INHABITANT

    Nov 1, 2004, 00:00

  • PDB34 A PHARMACOECONOMIC ANALYSIS OF THE USE OF AN INTENSIVE STRATEGY FOR TREATMENT OF PATIENTS WITH DIABETES MELLITUS TYPE 2 (DM T2)

    Nov 1, 2004, 00:00

  • PIN18 ASSESSING THE COST-EFFECTIVENESS OF DROTRECOGIN ALFA (ACTIVATED) IN SEVERE SEPSIS IN POLAND

    Nov 1, 2004, 00:00

  • PUK4 PATIENT PERCEPTION OF OAB DRUG THERAPY SUCCESS IS ASSOCIATED WITH LESS HEALTHCARE RESOURCE USE

    Nov 1, 2004, 00:00

  • PIN3 LINEZOLID FOR THE TREATMENT OF SKIN AND SOFT-TISSUE MRSA INFECTIONS-A COST-EFFECTIVE ALTERNATIVE TO VANCOMYCIN- EVIDENCE FROM A MULTINATIONAL CLINICAL TRIAL

    Nov 1, 2004, 00:00

  • PBR11 QUALITY OF LIFE IS ASSOCIATED TO ORTHOPEDIC STATUS IN HEMOPHILIACS WITH INHIBITORS

    Nov 1, 2004, 00:00

  • PCVI0 THE COST-EFFECTIVENESS OF CLOPIDOGREL IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN SWEDEN- AN ANALYSIS OF PCI-CURE

    Nov 1, 2004, 00:00

  • PCN30 IMPROVED TOXICITY PROFILE OF PEMETREXEDVS DOCETAXEL IN PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER PATIENTS TRANSLATES TO COST SAVINGS IN SPAIN

    Nov 1, 2004, 00:00

  • PIN8 ECONOMIC EVALUATION OF HIV TREATMENTS- THE I.CO.N.A. COHORT STUDY

    Nov 1, 2004, 00:00

  • UC1 HEALTH ECONOMIC COMPARISON OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION WITH MULTIPLE DAILY INJECTION FOR THE TREATMENT OF TYPE 1 DIABETES IN THE UK

    Nov 1, 2004, 00:00

  • PES25 ASSOCIATION BETWEEN VITAMIN SUPPLEMENTS USAGE AND PRESENCE OF AGE-RELATED MACULAR DEGENERATION IN A LATINO POPULATION ADJUSTING FOR SELECTION BIAS USING PROPENSITY SCORES

    Nov 1, 2004, 00:00

  • PCV35 ECONOMIC ASSESSMENT OF SWITCHING TO EZETIMIBE CO-ADMINISTERED WITH SIMVASTATIN IN SPAIN FORA COHORT OF PATIENTS NOT AT GOAL ON ATORVASTATIN MONOTHERAPY

    Nov 1, 2004, 00:00

  • PAAI LEVOCETIRIZINE REDUCES THE COST OF PER AND ITS CO-MORBIDITIES FOR SOCIETY AND EMPLOYERS

    Nov 1, 2004, 00:00

  • PDB16 EFFECT OF PATIENT EDUCATION IN TYPE-2 DIABETES OVER 10 YEARS BASED ON A PROSPECTIVE DIABETES MODEL IN THE PROVINCE OF STYRIA, AUSTRIA

    Nov 1, 2004, 00:00

  • PES5 A COST-EFFECTIVENESS ANALYSIS OF LATANOPROST IN THE TREATMENT OF OPEN ANGLE GLAUCOMA IN SPAIN

    Nov 1, 2004, 00:00

  • POS7 PERSISTENCE AND COMPLIANCE WITH BISPHOSPHONATE THERAPY AMONG POST-MENOPAUSAL OSTEOPOROTIC WOMEN

    Nov 1, 2004, 00:00

  • PCV27 COST-EFFECTIVENESS OF BUPROPION IN SMOKING CESSATION IN FINLAND

    Nov 1, 2004, 00:00

  • PNL2 STROKE SEVERITY AND EARLY OUTCOMES AFTER FIRSTEVER ISCHEMIC STROKE

    Nov 1, 2004, 00:00

  • PMC4 CAN ECONOMIC EVALUATIONS BE MADE MORE TRANSFERABLE?

    Nov 1, 2004, 00:00

  • PDB22 COST-EFFECTIVENESS ANALYSIS OF THE DIABETES PREVENTION PROGRAM IN A SPANISH SETTING

    Nov 1, 2004, 00:00

  • PPN9 AGREEMENT BETWEEN PATIENTS- REPORTED OUTCOMES IN 3 CHRONIC DISEASES

    Nov 1, 2004, 00:00

  • CS2 COST-EFFECTIVENESS OF COMPETING ANTIPSYCHOTIC MONOTHERAPIES IN ACUTE BIPOLAR MANIA IN THE U.K.

    Nov 1, 2004, 00:00

  • PAA6 IMPACT OF A DISEASE MANAGEMENT PROGRAM ON CONTROL OF ASTHMA IN NORMANDY

    Nov 1, 2004, 00:00

  • CN2 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB CHOP VERSUS CHOP IN PATIENTS WITH AGGRESSIVE NONHODGKIN LYMPHOMA

    Nov 1, 2004, 00:00

  • PCN23 A COST MINIMIZATION ANALYSIS OF FIRST-LINE POLYCHEMOTHERAPY REGIMENS IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER

    Nov 1, 2004, 00:00

  • PMH6 HEALTH EFFECTS AND HEALTH CARE RESOURCE UTILIZATION IN POLISH SCHIZOPHRENIC OUTPATIENTS INITIATING OR CHANGING TO OLANZAPINE OR TYPICAL ANTIPSYCHOTIC MONOTHERAPY- ANALYSIS OF 12-MONTH DATA FROM SOHO STUDY

    Nov 1, 2004, 00:00

  • PES8 RESOURCE UTILIZATION OF END-STAGE GLAUCOMA PATIENTS RECEIVING LOW VISION CARE- A US MULTI-SITE RETROSPECTIVE STUDY

    Nov 1, 2004, 00:00

  • PMW6 SHORT-TERM AND LONG-TERM PSYCHOSOCIAL CONSEQUENCES OF FALSE POSITIVE SCREENING MAMMOGRAPHY-DEVELOPMENT OF TWO NEW QUESTIONNAIRE BASED ON THE PSYCHOLOGICAL CONSEQUENCES QUESTIONNAIRE (THE PCQ)

    Nov 1, 2004, 00:00

  • PDB3 COST-EFFECTIVENESS ANALYSIS OF INSULIN DETEMIR COMPARED TO NPH INSULIN IN PATIENTS WITH TYPE-2 DIABETES IN THE UNITED KINGDOM

    Nov 1, 2004, 00:00

  • POS5 MEDICO-ECONOMIC EVALUATION OF VERTEBRAL FRACTURE IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN

    Nov 1, 2004, 00:00

  • PHP16 PHARMACOECONOMICS INTRODUCTION IN THE CREATION OF POSITIVE DRUG LIST IN BULGARIA

    Nov 1, 2004, 00:00

  • PHP17 MEDICINAL CANNABIS IN THE NETHERLANDS

    Nov 1, 2004, 00:00

  • PHP23 ANALYSIS OF CLINICAL INTERVENTION DOCUMENTATION BY PHARMACISTS

    Nov 1, 2004, 00:00

  • MC5 ANNUAL BURDEN OF DRY EYE SYNDROME IN SIX EUROPEAN COUNTRIES

    Nov 1, 2004, 00:00

  • POB1 OBESITYANDTHE RISK OF UPPER RESPIRATORY TRACT INFECTIONS

    Nov 1, 2004, 00:00

  • PBR3 ECONOMIC MODELING OF ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN-FREE METHOD (RAHFPFM)- VALUE OF POTENTIAL VIRAL TRANSMISSION REDUCTION DUE TO PLASMA/ALBUMIN-FREE FORMULATION

    Nov 1, 2004, 00:00

  • QL3 QUALITY OF LIFE OF GASTROESOPHAGEL REFLUX DISEASE PATIENTS

    Nov 1, 2004, 00:00

  • PCV79 THE COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE TYPE 2 DIABETIC PATIENTS WITH MICROALBUMINURIA IN CHINA

    Nov 1, 2004, 00:00

  • PCV29 COST-EFFECTIVENESS OF REDUCTION IN CARDIOVASCULAR OUTCOMES WITH ATORVASTATIN IN PATIENTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL LEVELS.TREATED FOR HYPERTENSION- THE ASCOT-LLA STUDY

    Nov 1, 2004, 00:00

  • PCNI4 ALCEA (ADVANCED LUNG CANCER ECONOMIC ASSESSMENT)

    Nov 1, 2004, 00:00

  • PCV9 COST-EFFECTIVENESS ANALYSIS OF ALTEPLASE COMPARED WITH STREPTOKINASE AND ABSENCE OF THROMBOLYTICAL THERAPY FOR MYOCARDIAL INFARCTION

    Nov 1, 2004, 00:00

  • PES14 RESPONSIVENESS OF SELF-REPORTED VISUAL FUNCTIONING IN AGE-RELATED MACULAR DEGENERATION (AMD) PATIENTS TO GENERAL HEALTH AND CHANGES IN VISUAL ACUITY IN A PHASE I/II RANDOMIZED CONTROLLED TRIAL OF LUCENTISTM (RANIBIZUMAB; RHUFAB V2)

    Nov 1, 2004, 00:00

  • PAR8 HEALTH ECONOMIC EVALUATION OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH ADALIMUMAB

    Nov 1, 2004, 00:00

  • PUK11 COST-CONSEQUENCES OF TREATING WOMEN WITH STRESS URINARY INCONTINENCE WITH DULOXETINE FROM THE PERSPECTIVE OF THE STATUTORY HEALTH INSURANCE IN GERMANY

    Nov 1, 2004, 00:00

  • PDB24 CONTINGENT VALUATION OF AN INHALED DELIVERY SYSTEM FOR INSULIN

    Nov 1, 2004, 00:00

  • PMH13 THE COST-EFFECTIVENESS OF PAROXETINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER IN JAPAN

    Nov 1, 2004, 00:00

  • PMC23 REVIEW AND ASSESSMENT OF THE ECONOMIC EVALUATION STUDIES ON HEALTH CARE IN MEXICO

    Nov 1, 2004, 00:00

  • PDB23 COST-EFFECTIVENESS OF ACARBOSE FOR THE MANAGEMENT OF IMPAIRED GLUCOSE TOLERANCE IN SWEDEN

    Nov 1, 2004, 00:00

  • PCV38 COSTS OF MYOCARDIAL INFARCTION TREATMENT IN RUSSIAN FEDERATION

    Nov 1, 2004, 00:00

  • DB2 LABOR MARKET EFFECTS OF INSULIN DEPENDENT AND NON-INSULIN DEPENDENT DIABETES AMONG CANADIAN LABOR FORCE

    Nov 1, 2004, 00:00

  • PCV60 TREATMENT OF NEWLY-DIAGNOSED HYPERTENSIVE PATIENTS IN ITALYA RETROSPECTIVE COHORT STUDY IN PRIMARY CARE

    Nov 1, 2004, 00:00

  • IN2 IS PROVISION OF ANTI-VIRAL INFLUENZA TREATMENT A SOUND INVESTMENT FOR PRIVATE AND PUBLIC EMPLOYERS IN THE UK?

    Nov 1, 2004, 00:00

  • PGI2 THE ECONOMIC EVALUATION OF A RANDOMIZED TRIAL COMPARING 'TEST-AND-TREAT' WITH PROMPT ENDOSCOPY IN PRIMARY CARE; THE HEALTH ECONOMICS OF THE SENSE-STUDY

    Nov 1, 2004, 00:00

  • PIN2 COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN SUSPECTED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN NOSOCOMIAL PNEUMONIA IN GERMANY

    Nov 1, 2004, 00:00

  • PMC5 ARE THE BEST AVAILABLE, MOST APPLICABLE CLINICAL EFFECTIVENESS DATA USED IN ECONOMIC EVALUATIONS OF DRUG THERAPIES?

    Nov 1, 2004, 00:00

  • PES3 ANALYSIS OF CLINICAL EFFICACY OF LATANOPROST VS. THE MOST FREQUENT TREATMENT PATTERN FOR PRIMARY OPEN ANGLE GLAUCOMA (POAG) AND OCULAR HYPERTENSION (OH) IN POLAND

    Nov 1, 2004, 00:00

  • PCV48 ARIAL FIBRILLATION HISTORY AND ATRIOVENTRICULAR BLOCK APPEARANCE IN PATIENTS WITH SINUS NODE DISEASE AND SINGLE CHAMBER ATRIAL PACEMAKER-IMPACT ON COST OF THERAPY

    Nov 1, 2004, 00:00

  • PUK22 DERIVING UNIT COSTS FOR RESOURCE UTILISATION IN PROSPECTIVE URINARY INCONTINENCE RESEARCH (PURE)-AN OBSERVATIONAL STUDY IN 14 EUROPEAN COUNTRIES

    Nov 1, 2004, 00:00

  • PCN37 DIFFERENCES IN TREATMENT PRACTICE, RESPONSE RATES AND COST OF EPOETIN ALFA AND DARBEPOETIN ALFA TREATMENT FOR ANEMIC CANCER PATIENTS- A RETROSPECTIVE ANALYSIS FROM SWEDEN

    Nov 1, 2004, 00:00

  • PMH10 ECONOMIC ANALYSIS OF RISPERIDONE LONG-ACTING INJECTION IN NEW ZEALAND

    Nov 1, 2004, 00:00

  • PCV25 SMOKING CESSATION FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE-A COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2004, 00:00

  • PUK7 WHEN SHOULD ERYTHROPOIETIN (EPO) BE REPLACED BY PACKED RED BLOOD CELL TRANSFUSION (TR) IN HEMODIALYSIS (HD) PATIENTS?

    Nov 1, 2004, 00:00

  • PMC20 DEVELOPMENT OF A NUTRITION RELATED QUALITY OF LIFE SCALE IN CHILDREN

    Nov 1, 2004, 00:00

  • PPN2 RESOURCE UTILISATION OF PATIENTS WITH CHRONIC PAIN CONDITIONS BEFORE AND DURING TREATMENT WITH LONG-ACTING OPIOIDS IN GERMANY

    Nov 1, 2004, 00:00

  • MH1 INCREMENTAL COST-EFFECTIVENESS OF THREE CLASSES OF ANTI-DEPRESSANTS- RESULTS FROM A UK RANDOMISED TRIAL

    Nov 1, 2004, 00:00

  • PHP21 QUALITY ASSESSMENT OF AN AMBULATORY CARE CLINIC BASED COLLABORATIVE CARE APPROACH FOR ACHIEVING THERAPEUTIC GOALS

    Nov 1, 2004, 00:00

  • PGI7 COST BENEFIT ANALYSIS OF TWO TREATMENTS FOR PATIENTS WITH CHOLEDOCHOLITHIASIS AND CHOLECYSTOLITHIASIS

    Nov 1, 2004, 00:00

  • PCV47 DECISION ANALYSIS ON EFFECTIVENESS AND COST-EFFECTIVENESS OF DISEASE MANAGEMENT PROGRAMS FOR THE TREATMENT OF HEART FAILURE

    Nov 1, 2004, 00:00

  • PCV50 CHRONIC VENOUS DISEASE- PATIENTS PROFILE

    Nov 1, 2004, 00:00

  • PCV68 POPULATION IMPACT OF LOSARTAN USE ON STROKE IN FRANCE

    Nov 1, 2004, 00:00

  • PMC2 A FRAMEWORK FOR HANDLING UNCERTAINTY AND VARIABILITY IN THE ECONOMIC EVALUATION OF HEALTH CARE PROGRAMS

    Nov 1, 2004, 00:00

  • POS8 PERSISTENCE WITH BISPHOSPHONATE THERAPY AND THE IMPACT OF DOSING FREQUENCY IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS

    Nov 1, 2004, 00:00

  • PCVI5 COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH HYPERTENSION AND LVH IN SPAIN- AN ECONOMIC EVALUATION BASED ON THE LIFE TRIAL

    Nov 1, 2004, 00:00

  • PCNI8 A COST COMPARISON OF GEMZAR PLUS CISPLATIN WITH OTHER NOVEL AGENTS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ITALY

    Nov 1, 2004, 00:00

  • PMC14 PERSONAL DRUG UTILIZATION REPORT (PDUR)-A CONTRIBUTION TO COST REDUCTION AND PATIENT EMPOWERMENT

    Nov 1, 2004, 00:00

  • PMW5 INFERTILITY TREATMENT POLICIES IN GERMANY AND THE UNITED KINGDOM-WILLINGNESS TO PAY AMONG AFFECTED COUPLES

    Nov 1, 2004, 00:00

  • DB1 ASSOCIATION BETWEEN ANTIPSYCHOTIC DRUGS AND DIABETES MELLITUS- A PHARMO STUDY

    Nov 1, 2004, 00:00

  • PCN33 HEALTH UTILITY VALUES FOR CANCER RELATED ANAEMIA

    Nov 1, 2004, 00:00

  • MC6 PRODISQ A MODULAR QUESTIONNAIRE ON PRODUCTIVITY AND DISEASE FOR ECONOMIC EVALUATION STUDIES IN PATIENT SETTINGS AND ORGANISATIONAL SETTINGS

    Nov 1, 2004, 00:00

  • PPN8 RESPONSIVENESS OF THE SHUTTLE WALKING TEST COMPARED WITH DISEASE SPECIFIC AND GENERIC OUTCOME MEASURES IN PATIENTS WITH CHRONIC BACK PAIN

    Nov 1, 2004, 00:00

  • PCV20 COST EFFECTIVENESS OF ANTIHYPERTENSIVE MONO-THERAPYWITH PERINDOPRIL OR ENALAPRIL IN ELDERLY PATIENTS FROM THE THIRD PARTY PAYER PERSPECTIVE

    Nov 1, 2004, 00:00

  • PCV26 THE COST-EFFECTIVENESS OF EXTENDED ANTITHROMBOTIC PROPHYLAXIS FOLLOWING TOTAL HIP ARTHROPLASTY

    Nov 1, 2004, 00:00

  • PCN39 QUALITY ASSURANCE IN CANCER CHEMOTHERAPY THROUGH PHARMACEUTICAL CARE DOCUMENTATION

    Nov 1, 2004, 00:00

  • PC02 ITEM SELECTION FOR COPD-SPECIFIC UTILITY INSTRUMENT

    Nov 1, 2004, 00:00

  • PAR5 MESSAGE- AN OBSERVATIONAL POST-LAUNCH STUDYTO ASSESS EFFECTIVENESS AND COST OF SUPLASYN IN PATIENTS WITH KNEE OSTEOARTHRITIS

    Nov 1, 2004, 00:00

  • PGI5 COSTS BENEFITS WITH ESOMEPRAZOLE 20MG 'ONDEMAND' TREATMENT IN GASTROESOPHAGEAL REFLUX DISEASE (GERD) PATIENTS IN BELGIUM

    Nov 1, 2004, 00:00

  • PMH3 FOLLOW-UP OF SCHIZOPHRENIA PATIENTS DISCHARGED ON RISPERIDONE OR OLANZAPINE- A TIME-TO-EVENT ANALYSIS

    Nov 1, 2004, 00:00

  • CV3 NURSING HOME RESIDENTS WITH STROKE- CHANGES IN MANAGEMENT LEVELS AND COSTS OVER A SIX YEAR PERIOD

    Nov 1, 2004, 00:00

  • HP7 STRATEGIES OF PRIORIZATION BASED ON THE SOCIAL WELFARE FUNCTION

    Nov 1, 2004, 00:00

  • PCV39 MODELING THE ECONOMIC CONSEQUENCES OF IMPLANTING DUAL CHAMBER VS. SINGLE CHAMBER PACEMAKERS IN THE UK

    Nov 1, 2004, 00:00

  • PCN35 VALUATION OF SOCIETAL PREFERENCE BETWEEN THERAPIES FOR CANCER-RELATED ANAEMIA (CRA)- RECOMBINANT HUMAN ERYTHROPOETIN (RH-EPO) VERSUS BLOOD TRANSFUSION

    Nov 1, 2004, 00:00

  • PES11 ESTIMATION OF NATIONWIDE COSTS OF ANNUAL ASSISTANCE ATTRIBUTABLE TO VISUAL IMPAIRMENT, FROM AN ACTIVITY OF DAILY LIVING QUESTIONNAIRE

    Nov 1, 2004, 00:00

  • PMW3 IMPROVING THE DELIVERY OF CHILD AND MATERNAL HEALTH CARE IN A POOR SETTING- COSTS AND BARRIERS TO BE CONSIDERED IN THE IMPLEMENTATION OF WHO MOTHER-BABY PACKAGE IN MORELOS, MEXICO

    Nov 1, 2004, 00:00

  • PHP38 USE OF PATIENT-REPORTED OUTCOMES IN EVALUATION OF HEART FAILURE DEVICE THERAPY- THE REGULATORY PERSPECTIVE

    Nov 1, 2004, 00:00

  • POB3 EVALUATION OF THE COST-UTILITY OF ORLISTAT (XENICAL) IN THE UNITED KINGDOM

    Nov 1, 2004, 00:00

  • PGI10 HEALTH RELATED QUALITY OF LIFE AMONG POLISH GASTROESOPHAGEAL REFLUX DISEASE PATIENTS

    Nov 1, 2004, 00:00

  • PCV37 ECONOMIC EVALUATION OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY (TEE) GUIDED CARDIOVERSION IN THE ANTICOAGULATION IN CARDIOVERSION USING ENOXAPARIN (ACE) TRIAL FROM THE PERSPECTIVE OF STATUTORY HEALTH INSURANCE (SHI) IN GERMANY

    Nov 1, 2004, 00:00

  • PMH16 TOTAL HEALTH CARE CONSUMPTION AND COSTS OF SICKNESS FUND INSURED PATIENTS IN THE NETHERLANDS

    Nov 1, 2004, 00:00

  • POB4 EVALUATING THE IMPACT OF WEIGHT LOSS ON QUALITY OF LIFE IN PATIENTS TAKING ORLISTAT AND ENROLLED IN THE MOTIVATION, ADVICE AND PRO-ACTIVE SUPPORT (MAP) PROGRAMME

    Nov 1, 2004, 00:00

  • PCV54 USE OF VISUAL ANALOGUE SCALE (VAS) AS A METHOD OF DISCRIMINATION FOR PHYSICAL DISABILITY SEVERITY IN STROKE

    Nov 1, 2004, 00:00

  • PC03 DEVELOPMENT OF A COPD SEVERITY SCORE IN CLAIMS DATABASE

    Nov 1, 2004, 00:00

  • PMH9 A PROBABILISTIC COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM, GENERIC CITALOPRAM AND VENLAFAXINE AS A FIRST-LINE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN THE UNITED KINGDOM

    Nov 1, 2004, 00:00

  • PPT1 COST-OF-ILLNESS STUDY IN ACROMEGALIC PATIENTS IN ITALY

    Nov 1, 2004, 00:00

  • PUK5 ECONOMIC VALUATION OF THE EFFECTS OF DIETARY PROTEIN RESTRICTION ON THE PROGRESSION OF CHRONIC RENAL DISEASE

    Nov 1, 2004, 00:00

  • PIN24 IMPROVEMENT IN PATIENT-REPORTED DEPRESSION IN HIV PATIENTS EXPERIENCING GRADE 2 SIDE EFFECTS AFTER SUBSTITUTION OF THEIR PROTEASE INHIBITOR (PI)/NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) WITH LOPINAVIR/RITONAVIR (LPV/R)

    Nov 1, 2004, 00:00

  • PHP6 PRESCRIPTION PATTERN OF ALIMENTARYTRACT DRUGS AFTER CHANGES OF DRUG BENEFIT STATUS IN KOREA

    Nov 1, 2004, 00:00

  • PBR2 ECONOMIC IMPACT OF ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN-FREE METHOD (RAHF-PFM) IN PATIENTS WITH HEMOPHILIA A

    Nov 1, 2004, 00:00

  • POS2 CLINICAL AND ECONOMIC IMPACT OF RISEDRONATE TREATMENT FOR POST-MENOPAUSAL OSTEOPOROSIS IN FRANCE

    Nov 1, 2004, 00:00

  • EE2 LIVING WITH A DERMATOSIS- A NATIONAL SURVEY OF DEPRESSIVE SYMPTOMATOLOGY IN BELGIUM

    Nov 1, 2004, 00:00

  • PCN27 PATIENT PREFERENCE FORANASTROZOLE AS ADJUVANT HORMONAL THERAPY FOR EARLY BREAST CANCER (EBC) USING DISCRETE CHOICE WILLINGNESS-TO-PAY (WTP) METHODOLOGY

    Nov 1, 2004, 00:00

  • PHP32 LOSS PROFILES DERIVED FROM ACTIVITY OF DAILY LIVING SCORES ATTRIBUTABLE TO HANDICAPS

    Nov 1, 2004, 00:00

  • PPN7 USE OF THE NEUROPATHIC PAIN SCALE IN AN INTERNATIONAL STUDY

    Nov 1, 2004, 00:00

  • MC8 COMPARING THE INTERVAL PROPERTIES OF HEALTH-STATE VALUATIONS MEASURED USING THE VISUAL ANALOGUE SCALE AND RANK-BASED SCALING

    Nov 1, 2004, 00:00

  • PIN19 A COMPARISON OF COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS) VERSUS INTERFERON ALFA-2B PLUS RIBAVIRIN AS FIRST TREATMENT OF CHRONIC HEPATITIS C IN THE UK

    Nov 1, 2004, 00:00

  • HP4 DRUG COSTS DEVELOPMENT AFTER PATENT EXPIRY IN THE THE NETHERLANDS

    Nov 1, 2004, 00:00

  • PAA7 A COMPARISON OF TWO APPROACHES TO ESTIMATE ANNUAL MEDICATION COSTS IN THE KORA ASTHMA AND ALLERGY STUDY

    Nov 1, 2004, 00:00

  • PCV28 COST-EFFECTIVENESS OF RAMIPRIL IN PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS- A SWISS PERSPECTIVE

    Nov 1, 2004, 00:00

  • PAA5 A COMPARATIVE ANALYSIS OF EFFICACY, SAFETY AND COST-EFFECTIVENESS OF FLUTICASONE AND MONTELUCAST IN THERAPY OF BRONCHIAL ASTHMA

    Nov 1, 2004, 00:00

  • PDB20 COST AND OUTCOMES OF THE DIABETES CLINIC IN A COMMUNITY HOSPITAL, MAE HONG SON, THAILAND

    Nov 1, 2004, 00:00

  • PUK20 IMPLICATIONS OF OVERACTIVE BLADDER ICD-9 CODE CHANGES AND USE OF CODES IN A MANAGED CARE POPULATION

    Nov 1, 2004, 00:00

  • PHP25 WILLINGNESS TO PAY VERSUS OUT OF POCKET PAYMENTS FOR HEALTH SERVICES UTILIZATION IN GREECE

    Nov 1, 2004, 00:00

  • PUK12 LONG-TERM COST-EFFECTIVENESS MODELLING OF FEEDBACK MICROWAVE THERMOTHERAPY VERSUS DRUG TREATMENT IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA AND LOWER URINARY TRACT SYMPTOMS

    Nov 1, 2004, 00:00

  • PHP14 ECONOMIC ASPECTS OF INDIVIDUAL TREATMENT IN POLAND-OUT-PATIENT VIEWPOINT

    Nov 1, 2004, 00:00

  • PCN4 COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER

    Nov 1, 2004, 00:00

  • PCNI5 GEMZAR RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIALS (GREAT2)- A PATIENT-LEVEL COST COMPARISON OF THREE CHEMOTHERAPY REGIMENS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN FRANCE

    Nov 1, 2004, 00:00

  • PNL16 A COMPARATIVE STUDY ON RESOURCE USE, COSTS AND CAREGIVER BURDEN BETWEEN RASAGILINE AND ENTACAPONE IN FLUCTUATING PARKINSONS DISEASE (PD) PATIENTS

    Nov 1, 2004, 00:00

  • PAR3 QUANTIFYING DISEASE SEVERITY AS A DETERMINANT OF COSTS AND QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS IN AUSTRALIA

    Nov 1, 2004, 00:00

  • PCV41 COST-EFFECTIVENESS OF PHARMACEUTICAL TREATMENTS OF HYPERCHOLESTEROLEMIA IN CATALONIA, SPAIN

    Nov 1, 2004, 00:00

  • PCNI3 COST-EFFECTIVENESS ANALYSIS OF ADVANCED NON-SMALL CELL LUNG CANCER TREATMENT WITH CISPLATIN-ETOPOSIDE, CISPLATIN-WINORELBINE AND CISPLATIN-GEMCYTABINE

    Nov 1, 2004, 00:00

  • PNL8 COST-EFFECTIVENESS OF THROMBOLYSIS WITH RT-PA FOR ACUTE ISCHEMIC STROKE IN TAIWAN

    Nov 1, 2004, 00:00

  • PIN29 ECONOMIC EVALUATION OF MENINGOCOCCAL C VACCINATION PROGRAMMES AND ITS IMPACT ON DECISION MAKING

    Nov 1, 2004, 00:00
  • «
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170 (current)
  • »